EGFR-TKI序贯化疗治疗EGFR-TKI获得性耐药晚期非小细胞肺癌的临床分析
Clinical analysis of EGFR-TKI sequential chemotherapy in the treatment of EGFR-TKI-acquired advanced non-small cell lung cancer
王玮 1郭亮2
作者信息
- 1. 宝鸡市中心医院 呼吸内科,陕西 宝鸡 721008
- 2. 宝鸡市中心医院 心血管内科,陕西 宝鸡 721008
- 折叠
摘要
目的 研究EGFR-TKI序贯化疗治疗EGFR-TKI获得性耐药晚期非小细胞肺癌(NSCLC)的临床疗效.方法 将80例EGFR-TKI获得性耐药晚期NSCLC患者均分为2组.对照组单纯化疗,观察组行EGFR-TKI序贯化疗治疗.比较2组治疗后生活质量和不良反应产生情况.结果 观察组治疗效果优于对照组(P<0.05);2组均出现了恶心、呕吐、脱发、白细胞减少和皮疹,组间比较白细胞减少和皮疹发生率差异具有统计学意义(P<0.05).结论 EGFR-TKI序贯化疗治疗EGFR-TKI耐药晚期NSCLC有较好临床疗效,安全且能提高患者生存质量.
Abstract
Objective To study the clinical efficacy of EGFR-TKI sequential chemotherapy in the treatment of EGFR-TKI-acquired advanced non-small cell lung cancer (NSCLC). Methods 80 patients with EGFR-TKI acquired advanced NSCLC were divided into two groups. The control group was received chemotherapy alone; and the observation group was treated with EGFR-TKI sequential chemotherapy. The quality of life and the occurrence of adverse reactions were compared between the two groups. Results The clinical effect of the observation group was significantly higher than the control group (P<0.05); the cases in two groups had nausea, vomiting, alopecia, leukopenia and rash, there was a significant difference between the two groups in the incidence of leukopenia and rash (P<0.05). Conclusion EGFR-TKI sequential chemotherapy is effective in the treatment of EGFR-TKI-resistant advanced NSCLC with safety and could improve the quality of life of patients.
关键词
表皮生长因子受体-酪氨酸激酶抑制剂/序贯疗法/获得性耐药/晚期非小细胞肺癌Key words
epidermal growth factor receptor-tyrosine kinase inhibitor/sequential therapy/acquired resistance/advanced non-small cell lung cancer引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据